BR112022019047A2 - Peptídeos de domínio knob autônomos - Google Patents

Peptídeos de domínio knob autônomos

Info

Publication number
BR112022019047A2
BR112022019047A2 BR112022019047A BR112022019047A BR112022019047A2 BR 112022019047 A2 BR112022019047 A2 BR 112022019047A2 BR 112022019047 A BR112022019047 A BR 112022019047A BR 112022019047 A BR112022019047 A BR 112022019047A BR 112022019047 A2 BR112022019047 A2 BR 112022019047A2
Authority
BR
Brazil
Prior art keywords
autonomous
domain peptides
knob domain
isolated
formulations
Prior art date
Application number
BR112022019047A
Other languages
English (en)
Inventor
David Griffiths Lawson Alastair
Macpherson Alexander
Scott-Tucker Anthony
Spiliotopoulos Anastasios
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004462.4A external-priority patent/GB202004462D0/en
Priority claimed from GBGB2008095.8A external-priority patent/GB202008095D0/en
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of BR112022019047A2 publication Critical patent/BR112022019047A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PEPTÍDEOS DE DOMÍNIO KNOB AUTÔNOMOS. A presente descrição se refere a fragmentos isolados de anticorpos, em particular aos domínios knob isolados de CDR-H3 bovina ultralonga ou porções da mesma que se liga a um antígeno de interesse e formulações que compreendem os mesmos. A descrição se refere adicionalmente ao uso dos fragmentos de anticorpo isolados e formulações em terapia. A presente descrição também se estende aos métodos de preparar os ditos fragmentos de anticorpo isolados.
BR112022019047A 2020-03-27 2021-03-26 Peptídeos de domínio knob autônomos BR112022019047A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2004462.4A GB202004462D0 (en) 2020-03-27 2020-03-27 Antibody fragments
GBGB2008095.8A GB202008095D0 (en) 2020-05-29 2020-05-29 Antibody fragments
PCT/EP2021/057946 WO2021191424A1 (en) 2020-03-27 2021-03-26 Autonomous knob domain peptides

Publications (1)

Publication Number Publication Date
BR112022019047A2 true BR112022019047A2 (pt) 2022-11-01

Family

ID=75339748

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019047A BR112022019047A2 (pt) 2020-03-27 2021-03-26 Peptídeos de domínio knob autônomos

Country Status (14)

Country Link
US (1) US20240024520A1 (pt)
EP (1) EP4126936A1 (pt)
JP (1) JP2023519576A (pt)
KR (1) KR20220160069A (pt)
CN (1) CN115667298A (pt)
AU (1) AU2021245031A1 (pt)
BR (1) BR112022019047A2 (pt)
CA (1) CA3175034A1 (pt)
CL (1) CL2022002635A1 (pt)
CO (1) CO2022015049A2 (pt)
IL (1) IL296732A (pt)
MX (1) MX2022012021A (pt)
TW (1) TW202202520A (pt)
WO (1) WO2021191424A1 (pt)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060228364A1 (en) 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
EP2338900B1 (en) 2001-11-13 2014-01-01 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof
CA2469785C (en) 2001-12-17 2014-04-22 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
US7989594B2 (en) 2003-07-01 2011-08-02 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
CN102199626B (zh) 2003-09-30 2015-06-24 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
CN101203613B (zh) 2005-04-07 2012-12-12 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
SI2334705T1 (sl) 2008-09-26 2017-05-31 Ucb Biopharma Sprl Biološki produkti
ES2667258T3 (es) 2009-09-10 2018-05-10 Ucb Biopharma Sprl Anticuerpos multivalentes
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB0920324D0 (en) 2009-11-19 2010-01-06 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
CN103946237B (zh) 2011-11-11 2017-04-12 Ucb医药有限公司 白蛋白结合抗体及其结合片段
JP2015509091A (ja) * 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
US10048253B2 (en) 2012-06-28 2018-08-14 Ucb Biopharma Sprl Method for identifying compounds of therapeutic interest
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201310544D0 (en) 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
CN111518199A (zh) * 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201411420D0 (en) 2014-06-26 2014-08-13 Ucb Biopharma Sprl Antibody constructs
GB201811368D0 (en) 2018-07-11 2018-08-29 Ucb Biopharma Sprl Antibody

Also Published As

Publication number Publication date
KR20220160069A (ko) 2022-12-05
WO2021191424A1 (en) 2021-09-30
AU2021245031A1 (en) 2022-11-03
TW202202520A (zh) 2022-01-16
EP4126936A1 (en) 2023-02-08
CN115667298A (zh) 2023-01-31
IL296732A (en) 2022-11-01
CA3175034A1 (en) 2021-09-30
MX2022012021A (es) 2022-10-27
CO2022015049A2 (es) 2022-11-08
JP2023519576A (ja) 2023-05-11
US20240024520A1 (en) 2024-01-25
CL2022002635A1 (es) 2023-03-31

Similar Documents

Publication Publication Date Title
BR112021023229A2 (pt) Conjugados anticorpo-fármaco inibidores de mcl-1 e métodos de uso
AR115418A1 (es) ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
BR0207067A (pt) Método para identificar, isolar e produzir antìgenos para um patógeno especìfico e uso do mesmo
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
BR112013008407A2 (pt) antígenos de clostridium difficile
NO994983L (no) Fremgangsmåte for fremstilling av anti-humane antigenreseptorer, samt anvendelse av disse
BR112022000216A2 (pt) Anticorpos direcionados a dll3 e usos dos mesmos
BR112014030797A2 (pt) epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo
AU2018338322A1 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
BR112022011570A2 (pt) Anticorpos anti-mertk e métodos de uso dos mesmos
BR112022001733A2 (pt) Anticorpos anti-ms4a4a e métodos de uso dos mesmos
BR112022004575A2 (pt) Anticorpos de antígenos de vírus antioncolíticos e métodos de uso dos mesmos
BR9909026A (pt) Epìtopos nas proteìnas do envelope viral e anticorpos especìficos direcionados contra estes epìtopos; e uso para a detecção dos antìgenos virais do hcv no tecido do hospedeiro
BR112021026089A2 (pt) Fragmentos de ligação ao antígeno de cd3 e composições compreendendo os mesmos
GEP20043256B (en) Monoclonal Antibodies and Antibody Cocktail for Detection of Prion Protein as an Indication of Transmissible Spongiform Encephalopathies
BR112021016398A2 (pt) Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer
BR112021025077A2 (pt) Anticorpos anti-sortilina para uso em terapia
BR112022013403A2 (pt) Anticorpos anti-tigit, anticorpos multiespecíficos que compreendem os mesmos e métodos de uso dos mesmos
BR112021016791A2 (pt) Proteínas de ligação de antígenos que se ligam a bcma
BR112022001693A2 (pt) Construtos de proteína de ligação ao antígeno e usos dos mesmos
BR112022011037A2 (pt) Anticorpos ddr1 novos e usos dos mesmos
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
BR112021018632A2 (pt) Moléculas de ligação ao cd3
BR112017022205A2 (pt) anticorpo anti-vegfr2 humano para terapia de câncer antiangiogênica e objetivada
BR112022019047A2 (pt) Peptídeos de domínio knob autônomos